SCHEMBL48361

SCHEMBL48361

O=C(O)Oc1cccc([N+](=O)[O-])c1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.53
TSHR P16473 2/20 0.49
ALDH1A1 P00352 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TDP1 Q9NUW8 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
RECQL P46063 1/20 0.43
ESR2 Q92731 1/20 0.42
APEX1 P27695 1/20 0.42
HTT P42858 1/20 0.42
CYP1A2 P05177 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48360 1.00 GPR35 (0.53) GPR35TSHRALDH1A1MEN1KMT2A
SCHEMBL3206927 0.88 GPR35 (0.55) GPR35TSHRALDH1A1MEN1KMT2A
SCHEMBL48359 0.88 GPR35 (0.55) GPR35TSHRALDH1A1MEN1KMT2A
SCHEMBL11250446 0.87 GPR35 (0.50) GPR35TSHRALDH1A1MEN1KMT2A
SCHEMBL11250442 0.87 GPR35 (0.50) GPR35TSHRALDH1A1MEN1KMT2A
SCHEMBL17005575 0.85 TSHR (0.51) GPR35TSHRALDH1A1MEN1KMT2A
SCHEMBL1652615 0.85 GPR35 (0.51) GPR35TSHRALDH1A1MEN1KMT2A
SCHEMBL2373772 0.85 GPR35 (0.51) GPR35TSHRALDH1A1MEN1KMT2A
SCHEMBL57737 0.84 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ATDP1L3MBTL1
SCHEMBL57738 0.84 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114094175-A Secondary battery 珠海冠宇电池股份有限公司 2022-02-25 CN claimed
EP-2570416-B1 Antiviral bisfuran derivative as hiv protease inhibitor and intermediates thereof GILEAD SCIENCES INC (US) 2016-03-16 EP claimed
EP-1999133-B1 PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS GILEAD SCIENCES INC (US) 2013-08-21 EP claimed
US-20130172295-A1 PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2013-07-04 US claimed
US-8445734-B2 Photolabile protective groups for improved processes to prepare oligonucleotide arrays NIGU CHEMIE GMBH (DE) 2013-05-21 US claimed
EP-2570416-A1 Antiviral bisfuran derivative as hiv protease inhibitor and intermediates thereof Gilead Sciences, Inc. (US) 2013-03-20 EP claimed
US-8173623-B2 Process for preparation of HIV protease inhibitors GILEAD SCIENCES, INC. (US) 2012-05-08 US claimed
US-20110065631-A1 PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS GILEAD SCIENCES, INC (US) 2011-03-17 US claimed
US-20080004242-A1 Process for preparation of HIV protease inhibitors GILEAD SCIENCES, INC. 2008-01-03 US claimed
EP-1134248-B1 Process for the preparation of polycarbonate diols with a high molecular weight POLIMERI EUROPA SPA (IT) 2005-08-03 EP claimed
US-6384178-B2 COMPRISING TWO SUBSEQUENT REACTION STEPS, WHEREIN IN FIRST STEP POLYCARBONATE DIOL WITH MOLECULAR WEIGHT OF 500 TO 2000 IS SYNTHESIZED AND IN SECOND STEP MOLECULAR WEIGHT OF POLYCARBONATE DIOL IS INCREASED ENICHEM S.P.A. (IT) 2002-05-07 US claimed
US-20010047073-A1 Process for the preparation of polycarbonate diols with a high molecular weight ENICHEM S.P.A. (IT) 2001-11-29 US claimed
EP-1134248-A1 Process for the preparation of polycarbonate diols with a high molecular weight Enichem S.p.A. (IT) 2001-09-19 EP claimed
US-5446134-A Reacting bis(fluorosulfonyl)methane salt with cyanogen halide or pseudohalide CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1995-08-29 US claimed
US-20250281634-A1 CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY TUBULIS GMBH (DE) 2025-09-11 US disclosed
EP-4554984-A1 MANNOSYLATED AMINE DEXTRAN DRUG DELIVERY VEHICLES WITH DEGRADABLE DISULFIDE/CARBONATE LINKERS TARGETING PAYLOADS TO CD206 EXPRESSING CELLS Navidea Biopharmaceuticals, Inc. (US) 2025-05-21 EP disclosed
WO-2025072355-A1 METHODS FOR AND COMPOSITIONS OF NON-PEG BIOCONJUGATES WITH ULTRA-HIGH DRUG-TO-AGENT RATIO BIOHYBRID SOLUTIONS HOLDINGS, INC. (US) 2025-04-03 WO disclosed
WO-1995015352-A1 ALBUMIN BASED HYDROGEL UNIVERSITE DU QUEBEC A MONTREAL (CA) 1995-06-08 WO disclosed
EP-0410214-B1 PROCESS FOR THE PREPARATION OF N,N-DISUBSTITUTED MONO- AND OLIGOURETHANES BAYER AG (DE) 1993-08-18 EP disclosed
US-5221798-A Changing the regiopurity of mixtures containing 4,4'-disubstituted diphenyl carbonates AMOCO CORPORATION (US) 1993-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281634-A1 CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY CALCR, BCR, PTH1R GPR35 487/4885TSHR 214/4885ALDH1A1 1805/4885
US-20130172295-A1 PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS PRSS1, PREP, SERPINB1 GPR35 4829/4885TSHR 4789/4885ALDH1A1 2742/4885
US-20110065631-A1 PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS PREP, PRSS1, SERPINB1 GPR35 4825/4885TSHR 4819/4885ALDH1A1 1261/4885
US-20080004242-A1 Process for preparation of HIV protease inhibitors PRSS1, PREP, SERPINB1 GPR35 4829/4885TSHR 4789/4885ALDH1A1 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.